Loading
A phase 3 trial of Docetaxel in bladder & urothelial cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) is a phase 3 interventional study registered as NCT06857175 by Sichuan Baili Pharmaceutical Co., Ltd., with 508 participants planned, started 2025-03-25 and due to reach its primary completion in 2027-06. Interventions recorded: BL-B01D1 and Docetaxel or Paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Muscle-invasive and advanced bladder cancer, SystImmune / Sichuan Biokin, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, SystImmune / Sichuan Biokin, Bladder & urothelial cancer and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Cytotoxic chemotherapy and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Docetaxel, Bladder & urothelial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/